Wogonin, a flavonoid derived from the plant Scutellaria baicalinase's, has emerged as a promising candidate for sepsis management due to its multifaceted pharmacological properties. A comprehensive search of databases, including Google Scholar, Scopus, Web of Science, PubMed, and Embase, was conducted up to November 2025 using relevant keywords. In-vivo studies were assessed using the SYRCLE risk of bias tool, and in-vitro studies were evaluated with the OHAT risk of bias tool. A total of 449 articles were initially sourced, ultimately, 24 publications included in this systematic review. Evidence from various in-vivo and in-vitro studies indicates that wogonin exerts protective effects against sepsis-induced organ damage by modulating critical signalling pathways such as NF-κB, MAPK, and Nrf2/HO-1. Despite these promising findings, further clinical trials are necessary to establish the safety and efficacy of wogonin in human subjects suffering from sepsis.
A phytochemical investigation of Callicarpa integerrima resulted in the isolation of two previously undescribed clerodane diterpenoids, compounds 1 and 2, in addition to four known compounds (3-6). Structural determination of the new compounds was accomplished through a comprehensive investigation of their spectral data (1D and 2D NMR, HR-ESI-MS and UV/IR), and their absolute configurations were assigned by the comparison of the experimental and calculated ECD curves, supported by specific rotation data. LDH release in J774A.1 macrophages was used to evaluate the anti-inflammatory effects of compounds 1-6. Compound 2 revealed remarkable activity, with an IC50 of 5.12 ± 0.24 µM, compared to andrographolide (IC50 of 12.48 ± 0.60 µM), effectively inhibiting lipopolysaccharide and nigericin-induced pyroptosis in a dose-dependent manner, highlighting its potential as a promising NLRP3 inflammasome inhibitor for further development.

